隆平高科(000998.SZ):子公司隆平生物擬增資擴股並引入戰投新洋豐等
格隆匯 2 月 8日丨隆平高科(000998.SZ)公佈,公司控股子公司隆平生物技術(海南)有限公司(“隆平生物”)成立於2019年5月10日,註冊資本5000萬元,公司現持有隆平生物62.50%股權。
為滿足隆平生物的研發活動需要,隆平生物進行增資擴股並引入戰略投資者新洋豐農業科技股份有限公司(領投方,“新洋豐”)、姜任飛、湖州九碩股權投資合夥企業(有限合夥)(“九碩投資”)。新洋豐、姜任飛、九碩投資分別以人民幣5000萬元、2500萬元、2200萬元的價格認購隆平生物新增註冊資本人民幣500萬元、250萬元、220萬元,取得隆平生物全面稀釋基礎上8.38%、4.19%、3.68%的股權,剩餘溢價部分均計入隆平生物資本公積。公司放棄此次隆平生物增資的優先認繳出資權。
該事項已經公司決策委員會於2021年2月5日召開的2021年第二次(臨時)會議審議通過,各方於2021年2月6日簽署《投資協議》。此次增資完成後,隆平生物的註冊資本由5000萬元變更為5970萬元,公司對隆平生物的持股比例由62.50%變更為52.34%,隆平生物仍為公司控股子公司。
此次引入戰略投資者有利於推進公司生物技術戰略,增強公司轉基因性狀研發投入,提升公司在生物技術領域的競爭能力。後續,公司將與新洋豐開展產業協同合作探索,通過雙方產業運營優勢,建立種子和肥料市場渠道、客户資源的共享與協同機制,推進農作物種、肥、藥一體化戰略合作及落地,持續增強公司競爭優勢,提升盈利水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.